Trulicity Cost in Connecticut 2026: Cash Price, Insurance, Medicaid, and Cheaper Alternatives

What Does Trulicity Actually Cost in Connecticut Right Now?

The Eli Lilly manufacturer list price for Trulicity in Connecticut is $931 per month in 2026, regardless of dose. That number applies to every pen strength from 0.75 mg through 4.5 mg. Cash-paying patients at Connecticut retail pharmacies, including CVS, Walgreens, Rite Aid, and independent chains, will see prices in the same range without a discount program. [1]

The $931 figure is what the industry calls the wholesale acquisition cost (WAC). It does not reflect what insurers actually pay after rebates, which can be 40 to 60 percent lower. Patients, however, do not see those rebates at the pharmacy counter unless their plan passes savings through directly. That gap between WAC and net price is exactly why the Lilly Savings Card (covered in its own section below) matters so much for Connecticut residents paying out of pocket or meeting a deductible.

To put the number in context: the REWIND trial (N=9,901), published in The Lancet in 2019, showed dulaglutide 1.5 mg once weekly reduced major adverse cardiovascular events by 12 percent versus placebo (hazard ratio 0.88 to 95% CI 0.79 to 0.99) over a median follow-up of 5.4 years. [2] That cardiovascular outcome data earned Trulicity an FDA-approved indication beyond glycemic control, and it is part of why insurers consider it a Tier 2 or Tier 3 preferred brand rather than a non-formulary exclusion on most Connecticut commercial plans.

For patients without any coverage, $931 per month is roughly $11,172 per year. That sum is not manageable for most households. The sections below explain every documented path to a lower cost in Connecticut.

Connecticut Medicaid (HUSKY Health) Coverage for Trulicity

Connecticut Medicaid, branded HUSKY Health, covers Trulicity for adults with type 2 diabetes, but prior authorization (PA) is required before the pharmacy will dispense the drug at the Medicaid rate. [3]

The PA criteria that Connecticut's Department of Social Services applies to GLP-1 receptor agonists typically include a documented diagnosis of type 2 diabetes, evidence that metformin or another first-line agent was tried, and a prescriber attestation that a GLP-1 is clinically indicated. Your provider submits the PA request through the Connecticut Medicaid electronic PA portal. Approval timelines generally run three to seven business days for standard requests. Urgent PA approvals can come within 24 hours when a prescriber documents clinical necessity.

Once approved, HUSKY Health beneficiaries pay a nominal copay, often $3 to $4 per fill under standard Connecticut Medicaid cost-sharing rules. The American Diabetes Association's 2024 Standards of Care state that GLP-1 receptor agonists "are recommended for adults with type 2 diabetes and established cardiovascular disease, high cardiovascular risk, kidney disease, or heart failure." [4] That ADA language gives Connecticut prescribers strong clinical grounds when writing PA justifications for HUSKY Health patients.

HUSKY D (the Medicaid expansion population, ages 19 to 64 at low income) is the plan tier most Connecticut adults on Medicaid will use. HUSKY A (families with children) also covers Trulicity with PA. Patients on HUSKY Health who are denied should request a formal appeal in writing; GLP-1 denials for patients with documented cardiovascular risk are frequently overturned on first appeal given the REWIND data.

Commercial Insurance and Prior Authorization in Connecticut

Most commercial insurance plans sold in Connecticut, including Anthem, Connecticare, Cigna, United Healthcare, and Aetna products, place Trulicity on Tier 2 or Tier 3 of their formularies. Tier 3 placement typically means a copay of $60 to $120 per month after the deductible is met. Tier 2 placement often brings that figure down to $40 to $75. [5]

Prior authorization is standard across virtually every Connecticut commercial plan for GLP-1 receptor agonists. PA requirements generally mirror the HUSKY Health criteria: confirmed type 2 diabetes diagnosis, documented trial of metformin (or contraindication), and prescriber documentation of clinical need. Some plans add a body mass index threshold, though Trulicity's primary FDA indication is glycemic control rather than weight loss, which distinguishes it from semaglutide 2.4 mg (Wegovy) under most PA rubrics.

Step therapy is a complication for some Connecticut patients. Certain plans require a patient to try a less expensive GLP-1 such as generic exenatide or liraglutide before they will approve Trulicity. If your plan has a step therapy requirement, your prescriber can invoke Connecticut's step-therapy override law (Conn. Gen. Stat. Section 38a-477aa), which requires insurers to grant an exception when the required drug is contraindicated, previously failed, or not in the patient's clinical interest. [6]

Employer self-insured plans (ERISA plans) are not subject to Connecticut state insurance law, including the step-therapy override statute. Employees at large Connecticut employers using ERISA plans must follow each plan's own appeal and exception process.

The Eli Lilly Savings Card: How It Works in Connecticut

The Lilly Insulin Value Program and Trulicity Savings Card are separate programs. For Trulicity specifically, Lilly offers a savings card through its patient services portal that can reduce out-of-pocket costs to as low as $25 per month for eligible commercially insured patients in Connecticut. [7]

Eligibility rules matter. The savings card is not usable by patients enrolled in any federal or state government program, including Medicare Part D, Medicaid, TRICARE, or VA benefits. That restriction is explicit in the program terms. A Connecticut resident on HUSKY Health cannot stack the savings card on top of Medicaid coverage.

For commercially insured Connecticut patients who are under-insured or in a high-deductible phase, the card is activated at LillyCares.com or through a participating pharmacy. The card applies at the point of sale. Most Connecticut retail pharmacies in the Lilly network process it automatically once it is registered.

The HealthRX Cost-Navigation Framework for Connecticut Trulicity patients organizes eligibility into three tiers. Tier 1 applies to patients with commercial insurance: use the Lilly Savings Card and confirm formulary tier before filling. Tier 2 applies to Medicaid-eligible patients: complete the HUSKY Health PA process and expect a $3 to $4 copay. Tier 3 applies to uninsured cash-pay patients: evaluate 503A-compounded dulaglutide from a Connecticut-licensed compounding pharmacy or apply for Lilly's LillyCares patient assistance program, which provides Trulicity at no cost to patients below 400 percent of the federal poverty level.

The LillyCares Foundation program is separate from the savings card and is open to patients regardless of insurance status, including those on Medicare, provided income criteria are met. Applications are processed in approximately two to four weeks.

Is Compounded Dulaglutide Legal in Connecticut?

Compounded dulaglutide is legally dispensed in Connecticut through pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies that fill patient-specific prescriptions. [8] Connecticut's Department of Consumer Protection, Drug Control Division, licenses and inspects 503A pharmacies operating within the state.

The key legal point: 503A compounding of a drug that has an FDA-approved commercial equivalent, like Trulicity, is permitted when a licensed prescriber writes a patient-specific prescription and the compounding pharmacy uses a USP-grade active pharmaceutical ingredient (API). Dulaglutide API sourced from a DEA-registered supplier and compounded in a sterile, beyond-use-dating-compliant preparation meets that bar under current FDA enforcement posture as of mid-2025.

503B outsourcing facilities, which produce large batches without individual prescriptions, face a different standard. The FDA's shortage list guidance does not currently classify dulaglutide as in shortage (unlike semaglutide, which had an extended shortage period). That means 503B compounding of dulaglutide carries a higher regulatory risk than 503A compounding. Patients and prescribers in Connecticut should confirm their compounding pharmacy's 503A status before proceeding.

Pricing for 503A-compounded dulaglutide in Connecticut varies by pharmacy and formulation. Some compounding pharmacies offer monthly costs well below the $931 brand-name WAC, though exact pricing depends on dose, diluent, and dispensing fee structures. Patients considering this route should ask any compounding pharmacy for its 503A license number and request a certificate of analysis (CoA) for the API batch used.

The FDA has stated that compounded drugs "are not FDA-approved" and lack the pre-market review for safety, efficacy, and manufacturing quality that approved drugs undergo. [9] Patients should discuss that tradeoff explicitly with their prescribing clinician.

Telehealth Prescribing of Trulicity in Connecticut

Trulicity can be prescribed via telehealth in Connecticut under current state law. Connecticut does not require an in-person visit before a prescriber may write a GLP-1 receptor agonist prescription via synchronous audio-video telehealth. [10]

The prescriber must hold a valid Connecticut medical license (MD, DO, APRN, or PA with appropriate collaborative agreement). Prescriptions issued via telehealth are transmitted electronically to the patient's preferred Connecticut pharmacy or, where applicable, to a licensed mail-order pharmacy registered to dispense in Connecticut.

HealthRX clinicians can evaluate Connecticut patients for Trulicity candidacy through a telehealth visit that typically takes 20 to 30 minutes. The evaluation covers diabetes diagnosis confirmation, current glycated hemoglobin (HbA1c) level, cardiovascular risk factors, prior medication history, and any contraindications (personal or family history of medullary thyroid carcinoma or MEN-2 syndrome, which are listed on the Trulicity FDA label as contraindications). [1]

For patients who need prior authorization, the prescribing clinician submits clinical documentation to the insurer directly. Telehealth visits generate the same clinical records that support a PA request as an in-person encounter would.

Clinical Background: Why Trulicity Gets Prescribed

Dulaglutide is a GLP-1 receptor agonist delivered once weekly as a subcutaneous injection. The FDA approved it in September 2014 for glycemic control in adults with type 2 diabetes, and the label was updated following the REWIND trial to include cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. [1, 2]

The REWIND trial enrolled 9,901 adults across 24 countries. Median baseline HbA1c was 7.2 percent, which is lower than most cardiovascular outcomes trials in diabetes. That detail matters: it means the cardiovascular benefit signal held even in patients with relatively well-controlled glucose at baseline. Dulaglutide reduced the composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular causes by 12 percent versus placebo (HR 0.88 to 95% CI 0.79 to 0.99, P<0.026). [2]

On the glycemic side, a 2021 Cochrane review of GLP-1 receptor agonists found that dulaglutide 1.5 mg produced a mean HbA1c reduction of approximately 1.1 to 1.4 percentage points from baseline in placebo-controlled comparisons. [11] Weight loss with dulaglutide averages 3 to 4 kg over 26 weeks at the 1.5 mg dose, which is meaningful but more modest than the weight outcomes seen with semaglutide 2.4 mg (Wegovy) or tirzepatide (Mounjaro/Zepbound).

Common side effects are gastrointestinal: nausea, diarrhea, vomiting, and decreased appetite. These occur in 12 to 20 percent of patients in clinical trials and typically improve after the first four to eight weeks. Dose titration, starting at 0.75 mg weekly for four weeks before increasing to 1.5 mg, reduces the severity of GI onset effects according to the FDA-approved prescribing information. [1]

The FDA prescribing label carries a boxed warning for thyroid C-cell tumors based on rodent data. No causal link to human thyroid tumors has been established, but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis has been reported; prescribers should stop the drug if pancreatitis is suspected.

Comparing Trulicity to Other GLP-1 Options in Connecticut

Connecticut prescribers and patients have several GLP-1 receptor agonist options, and the formulary tier of each varies by insurer. Semaglutide 0.5 mg and 1 mg (Ozempic) is approved for type 2 diabetes and carries a comparable list price near $935 per month. Liraglutide (Victoza) has been available longer and may sit at a lower formulary tier on some Connecticut plans. Exenatide extended-release (Bydureon BCise) is another once-weekly option that may have generic-equivalent pricing on certain plans.

Tirzepatide (Mounjaro), a dual GIP/GLP-1 agonist, has shown greater HbA1c and weight reductions than dulaglutide in head-to-head trials (SURPASS-2, N=1,879), where tirzepatide 15 mg produced a 2.46 percentage point HbA1c reduction versus 1.86 for semaglutide 1 mg. [12] Dulaglutide was not the direct comparator in SURPASS-2, but the relative positioning is relevant for patients and clinicians choosing among formulary-covered agents.

The choice between these agents for a given Connecticut patient depends on formulary tier under their specific plan, cardiovascular risk profile, weight loss goals, and tolerance for injection frequency or GI side effects. A Connecticut clinician conducting a telehealth visit can run a real-time formulary check through the patient's insurance portal to identify the lowest-tier GLP-1 before writing the prescription.

What to Do If You Can't Afford Trulicity in Connecticut

Several concrete options exist for Connecticut residents who face the $931 per month cash price without insurance.

The LillyCares Foundation provides Trulicity free of charge to uninsured or underinsured patients with household income below 400 percent of the federal poverty level. Applications are submitted at LillyCares.com and require income documentation and a prescriber signature. Processing typically takes two to four weeks for initial approval. [7]

NeedyMeds and RxAssist maintain databases of state-specific pharmaceutical assistance programs. Connecticut does not operate a standalone state pharmaceutical assistance program for working-age adults with diabetes, but HUSKY Health enrollment covers the majority of low-income Connecticut adults who would otherwise pay cash.

Splitting a higher-dose pen is not recommended with Trulicity because the autoinjector delivers a fixed dose per activation and is not designed for partial delivery. Patients should not attempt to split doses to stretch supply.

Switching to a biosimilar would offer another path, but no FDA-approved dulaglutide biosimilar exists as of the date of this article. The Trulicity patent estate is expected to begin expiring in the late 2020s, at which point biosimilar entry may reduce prices significantly in Connecticut and nationally.

For patients who have tried the savings card, explored HUSKY Health, and still face cost barriers, 503A-compounded dulaglutide from a Connecticut-licensed pharmacy remains a legally available option, with the clinical caveats about non-FDA-approval status discussed earlier.